Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364931 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT05364931 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 54 participants.
The verdict
NCT05364931, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
Interventions
- DRUG Placebo
- DRUG Cotadutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2022-07-14 |
| Est. Completion | 2024-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05364931
The ClinicalTrials.gov registry entry for NCT05364931 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05364931 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05364931 about?
NCT05364931 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis". The purpose of this study is to evaluate the safety and efficacy of cotadutide in participants with non-cirrhotic NASH with fibrosis.
What is the current status of trial NCT05364931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2022-07-14. Estimated completion is 2024-04-19.
What interventions are being tested in trial NCT05364931?
The interventions under investigation include: Placebo (DRUG), Cotadutide (DRUG).
Who is sponsoring clinical trial NCT05364931?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.